Off-labelgebruik rituximab bij de ziekte van Castleman

N. Al-Rubaiee; W. Terpstra; M. Crul

Off-labelgebruik rituximab bij de ziekte van Castleman

Translated title of the contribution: Off-label rituximab for Castleman's disease

N. Al-Rubaiee
, W. Terpstra
, M. Crul^*

^*Corresponding author for this work

Utrecht University
Onze Lieve Vrouwe Gasthuis

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Multicentric Castleman's disease is a lymphoproliferative disorder with a very poor prognosis. Treatment with corticosteroids and different chemotherapeutics has been described, but as yet, no randomized clinical trials have been performed and there is no consensus on the therapy of choice for this disease. A recent publication describes a series of 24 patients who were treated with rituximab with impressive clinical outcome. Based on these findings, we treated a HIV-positive 58 year old male who presented with Castleman's disease with four weekly rituximab infusions in October 2007. He reached a complete remission and tolerated the therapy very well. He has remained symptom-free until the present.

Translated title of the contribution	Off-label rituximab for Castleman's disease
Original language	Dutch
Pages (from-to)	163-164
Number of pages	2
Journal	Pharmaceutisch Weekblad
Volume	144
Issue number	38
Publication status	Published - 18 Sept 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{968a79121bb94abba154a37a12735a54,

title = "Off-labelgebruik rituximab bij de ziekte van Castleman",

abstract = "Multicentric Castleman's disease is a lymphoproliferative disorder with a very poor prognosis. Treatment with corticosteroids and different chemotherapeutics has been described, but as yet, no randomized clinical trials have been performed and there is no consensus on the therapy of choice for this disease. A recent publication describes a series of 24 patients who were treated with rituximab with impressive clinical outcome. Based on these findings, we treated a HIV-positive 58 year old male who presented with Castleman's disease with four weekly rituximab infusions in October 2007. He reached a complete remission and tolerated the therapy very well. He has remained symptom-free until the present.",

author = "N. Al-Rubaiee and W. Terpstra and M. Crul",

year = "2009",

month = sep,

day = "18",

language = "Dutch",

volume = "144",

pages = "163--164",

journal = "Pharmaceutisch Weekblad",

issn = "0031-6911",

publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",

number = "38",

}

TY - JOUR

T1 - Off-labelgebruik rituximab bij de ziekte van Castleman

AU - Al-Rubaiee, N.

AU - Terpstra, W.

AU - Crul, M.

PY - 2009/9/18

Y1 - 2009/9/18

N2 - Multicentric Castleman's disease is a lymphoproliferative disorder with a very poor prognosis. Treatment with corticosteroids and different chemotherapeutics has been described, but as yet, no randomized clinical trials have been performed and there is no consensus on the therapy of choice for this disease. A recent publication describes a series of 24 patients who were treated with rituximab with impressive clinical outcome. Based on these findings, we treated a HIV-positive 58 year old male who presented with Castleman's disease with four weekly rituximab infusions in October 2007. He reached a complete remission and tolerated the therapy very well. He has remained symptom-free until the present.

AB - Multicentric Castleman's disease is a lymphoproliferative disorder with a very poor prognosis. Treatment with corticosteroids and different chemotherapeutics has been described, but as yet, no randomized clinical trials have been performed and there is no consensus on the therapy of choice for this disease. A recent publication describes a series of 24 patients who were treated with rituximab with impressive clinical outcome. Based on these findings, we treated a HIV-positive 58 year old male who presented with Castleman's disease with four weekly rituximab infusions in October 2007. He reached a complete remission and tolerated the therapy very well. He has remained symptom-free until the present.

UR - https://www.scopus.com/pages/publications/70349900543

M3 - Article

AN - SCOPUS:70349900543

SN - 0031-6911

VL - 144

SP - 163

EP - 164

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

IS - 38

ER -

Off-labelgebruik rituximab bij de ziekte van Castleman

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this